Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lesinurad. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 known ✓ | Q96S37 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 1.00 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lesinurad SCHEMBL842962 | 1.00 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL2265513 | 0.99 | SLC22A12 (0.98) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL11915750 | 0.96 | SLC22A12 (0.92) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL16500465 | 0.90 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1299832 | 0.90 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4735350 | 0.90 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL1299308 | 0.89 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1299461 | 0.89 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL15698391 | 0.89 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL29588047 | 0.89 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130853-A1 | METHOD OF TREATING GOUT BY TOPICAL APPLICATION OF NANO LINIMENT | Zhang, Boke (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130854-A1 | PREPARATION OF NANO LINIMENT FOR EXTERNAL TREATMENT OF GOUT | Zhang, Boke (US) | 2026-05-14 | — | — | US | claimed |
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| US-12583860-B2 | Processes for the preparation of multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour | APOTEX INC. (CA) | 2026-03-24 | — | — | US | claimed |
| US-12539273-B2 | External nano liniment for gout and preparation method thereof | Zhang, Boke (US) | 2026-02-03 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-01 | — | — | US | claimed |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-10-14 | — | — | US | claimed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| WO-2025026900-A1 | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF GOUT | UNIVERSITAT DE LES ILLES BALEARS (ES) | 2025-02-06 | — | — | WO | claimed |
| WO-2023131868-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-07-13 | — | — | WO | claimed |
| CN-106866560-B | Lesinurad synthesis method | 浙江美诺华药物化学有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-108947919-B | Novel preparation method of anti-gout drug Lesinurad and key intermediate thereof | 上海奥博生物医药股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20220347208-A1 | FORMULATIONS USING LITHIUM TO TREAT GOUT ARTHROPATHY | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-11-03 | — | — | US | claimed |
| US-20220288038-A1 | ABCC11 INHIBITOR | THE UNIVERSITY OF TOKYO (JP) | 2022-09-15 | — | — | US | claimed |
| EP-4034136-A1 | FORMULATIONS USING LITHIUM TO TREAT GOUT ARTHROPATHY | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-08-03 | — | — | EP | claimed |
| EP-4019048-A1 | ABCC11 INHIBITOR | The University of Tokyo (JP) | 2022-06-29 | — | — | EP | claimed |
| US-11365180-B2 | Resolution method for axis chiral enantiomers of lesinurad | CHINA RESOURCES SAIKE PHARMACEUTICAL CO., LTD. (CN) | 2022-06-21 | — | — | US | claimed |
| CN-114341120-A | ABCC11 inhibitor | 国立大学法人东京大学 | 2022-04-12 | — | — | CN | claimed |
| US-20220024777-A1 | NOVEL AMORPHOUS ACTIVE PHARMACEUTICAL INGREDIENTS COMPRISING SUBSTANTIALLY AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE | DISRUPTIVE PHARMA AB (SE) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288038-A1 | ABCC11 INHIBITOR | ABCC1, ABCC3, SLCO2B1 | SLC22A12 35/4885CYP2C9 1335/4885CYP2C19 1984/4885 |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | RBP4, RBP1, FABP1 | SLC22A12 1765/4885CYP2C9 1832/4885CYP2C19 3860/4885 |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | RBP4, RBP1, FABP1 | SLC22A12 706/4885CYP2C9 2950/4885CYP2C19 4071/4885 |
| US-12583860-B2 | Processes for the preparation of multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour | CFD, CFB, CALCR | SLC22A12 950/4885CYP2C9 483/4885CYP2C19 395/4885 |
| US-11365180-B2 | Resolution method for axis chiral enantiomers of lesinurad | CLK4, CLK1, CLK3 | SLC22A12 4629/4885CYP2C9 1592/4885CYP2C19 2093/4885 |
| US-12539273-B2 | External nano liniment for gout and preparation method thereof | NLRP3, NLRP1, LCT | SLC22A12 1596/4885CYP2C9 535/4885CYP2C19 650/4885 |
| US-20260130853-A1 | METHOD OF TREATING GOUT BY TOPICAL APPLICATION OF NANO LINIMENT | NLRP3, XDH, NLRP1 | SLC22A12 503/4885CYP2C9 150/4885CYP2C19 138/4885 |
| US-20260130854-A1 | PREPARATION OF NANO LINIMENT FOR EXTERNAL TREATMENT OF GOUT | LIPA, PNP, LIPC | SLC22A12 546/4885CYP2C9 1086/4885CYP2C19 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.